key: cord-0856784-3tj29a3z
authors: Campioli, Cristina Corsini; Cevallos, Edison Cano; Assi, Mariam; Patel, Robin; Binnicker, Matthew J.; O’Horo, John C.
title: Clinical Predictors and Timing of Cessation of Viral RNA Shedding in Patients with COVID-19
date: 2020-08-05
journal: J Clin Virol
DOI: 10.1016/j.jcv.2020.104577
sha: 40abb20af490b6010fa27302990559f386703d03
doc_id: 856784
cord_uid: 3tj29a3z

BACKGROUND: Molecular detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is key in the diagnosis of coronavirus disease 2019 (COVID-19) and has been widely used for followup of cases as a proxy for contagiousness. The persistence of SARS-CoV-2 RNA shedding in the context of clinical features and comorbidities is understudied. METHODS: We retrospectively reviewed laboratory-confirmed COVID-19 adult symptomatic cases at Mayo Clinic, eventually achieving cessation of viral RNA shedding (CVS), defined as two consecutive negative SARS-CoV-2 PCR results on nasopharyngeal swabs collected at least 24 hours apart. RESULTS: A total of 251 patients were included, median age was 53 years and 59% female. The most common symptoms at diagnosis were cough, myalgia, dyspnea, fever and chills. Myalgia, cough, anosmia, ageusia and sore throat were common at CVS, but fever and dyspnea were not observed. The median time from symptom onset to CVS was 23 days, and did not differ by symptoms. The weekly cumulative CVS rate was 2, 14, 44, 73, 91 and 95% at 1-6 weeks from symptom onset, respectively. Cough and fever were associated with a positive PCR test if tested within 2 weeks of symptoms (P < 0.05). Patients with asthma or immunosuppression were less likely to achieve CVS if tested 3 weeks into symptoms (P < 0.04). CONCLUSIONS: The cumulative CVS rate at 3 weeks from symptom-onset is 44% in our entire cohort. The findings of our study highlight the low yield of repeating a SARS-CoV-2 NP PCR test within 21 days of a laboratoryconfirmed COVID-19 diagnosis.

The COVID-19 pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), continues to expand after first being reported in China in December 2019. [1] Clinical presentation is heterogeneous, with fever, cough, and fatigue being the most common clinical symptoms. [2, 3] Given the challenges in defining this clinically, the World Health Organization has defined COVID-19 as any individual with a positive polymerase chain reaction (PCR) test regardless of symptoms [4] and this has led to reliance on PCR for the diagnosis and management of COVID-19.

There is growing evidence demonstrating that viral shedding begins before a patient is symptomatic, peaks at or shortly after symptom onset, and persists beyond symptom resolution. [5, 6] It is known that asymptomatic viral shedding enhances the transmissibility of SARS-CoV-2. [7] Studies on SARS-CoV-2 persistence report a median time from symptom onset to persistently negative SARS-CoV-2 PCR tests ranging from 11 to 31 days [6, [8] [9] [10] [11] [12] [13] with positive tests found as late as 55 days from symptom onset. [14] Severe disease, in particular, has been associated with prolonged viral RNA detection in several reports [15] [16] [17] [18] , and the presence of dyspnea, hypoxia, and tachypnea has also been associated with prolonged shedding in respiratory samples. [11] There have been questions as to whether this persistent RNA detection represents viable virus, and therefore, transmission risk.

Understanding viral dynamics of SARS-CoV-2 shedding in relation to symptom evolution and other underlying clinical factors has direct implications in diagnostic stewardship, implementation of effective infection prevention measures, and the development of public health strategies. Here, we aimed to evaluate clinical features as predictors for the cessation of SARS-CoV-2 RNA detection in a cohort of laboratory-confirmed COVID-19 cases.

We retrospectively reviewed laboratory-confirmed COVID-19 adult symptomatic cases who had a positive initial SARS-CoV-2 PCR nasopharyngeal (NP) swab and two subsequent negative SARS-CoV-J o u r n a l P r e -p r o o f 2 PCR NP swab test results at Mayo Clinic, Rochester from February 1, 2020, through May 15, 2020. We excluded deceased patients to capture those who achieved viral RNA clearance. Other sample sources (e.g., bronchoalveolar lavage, other respiratory samples) were excluded to avoid testing variability.

Cessation of viral RNA shedding (CVS) was considered to have been achieved on the date of the first of two consecutive negative SARS-CoV-2 PCR results on NP swabs collected at least 24 hours apart.

Demographic, clinical, and laboratory data from each patient were extracted from the electronic health record. Date of symptom onset, symptoms at diagnosis, date of first and subsequent positive SARS-CoV-2 PCR tests, and symptoms at the time of CVS was recorded. Symptoms were recorded based on the current Centers for Disease Control and Prevention (CDC) case definition. [19] Immunocompromised patients were defined as solid organ transplant recipients, patients who had an active hematologic malignancy, and/or who were on anti-neoplastic chemotherapy, immunomodulators, or other immunosuppressive drugs. Fever was defined as a temperature > 38.5C. Ambulatory cases were defined as those cases that were not hospitalized during the course of the illness. The study was approved by the Mayo Clinic Institutional Review Board (IRB ID: 20-002629).

SARS-CoV-2 PCR testing was performed using SARS-CoV-2 qualitative assays using the cobas 6800 / 8800 systems (Roche Molecular Systems), the Abbott m2000 system (Abbott) or a SARS-CoV-2 laboratory-developed test that has received emergency use authorization from the Food and Drug Administration. [20] Categorical variables were reported as counts and percentages using Chi-square or Fisher's exact test for comparison, as appropriate. Continuous variables were reported as mean and standard deviations, or medians and interquartile ranges (IQR) from the 25 th to the 75 th percentiles and compared using t-test or the Wilcoxon rank-sum test, as deemed appropriate. The difference in symptom prevalence at diagnosis and at CVS was tested using McNemar's test. Logistical regression was applied to assess for associations between symptoms, risk factors, and CVS. A log-rank test was applied for time-to-event J o u r n a l P r e -p r o o f analysis for CVS and clinical features. Statistical tests were two-tailed with p <0.05 considered significant. All analyses were performed using the R Project (R Foundation for Statistical Computing, Austria).

A total of 1,641 patients had a positive SARS-CoV-2 PCR test at our institution during the study period. Of these, 251 (15.2%) were adults with a positive SARS-CoV-2 PCR on an NP swab followed by CVS. For this group of patients, a total of 1,101 SARS-CoV-2 PCR tests were performed and reviewed, with a median of 4 tests (IQR 2) performed per patient.

Patient demographics and comorbidities are summarized in Table 1 

Symptoms at initial laboratory diagnosis and at CVS are summarized in Table 2 

The median time from symptom onset to the first positive PCR test result was 3 (IQR 6) days.

The median time from symptom onset to CVS was 23 (IQR 12) days, and this did not differ significantly when stratified by symptom (P=0.76; Figure 1 and 2). The median time from the first positive PCR to CVS was 17 (IQR 11) days, and this also did not differ significantly by symptom. The cumulative CVS rate at different intervals from symptom onset in all patients was 1.6% at 1 week, 13 (Figure 3 ).

In our study, the cumulative CVS rate at 2 weeks from symptom onset was 13.5%, and increased to 43.8% at 3 weeks post symptom onset, suggesting that testing after 3 weeks of symptoms might have a greater CVS yield. Patients with cough and fever at diagnosis were more likely to have a persistently positive SARS-CoV-2 PCR result if tested within 2 weeks of symptom onset. Similarly, patients with J o u r n a l P r e -p r o o f asthma and immunosuppression were less likely to achieve CVS is tested within 3 weeks from symptom onset, indicating an association between viral RNA shedding in these populations within 3 weeks of symptoms. It is not known, however, if this persistent viral RNA shedding translates into persistent infectivity.

Symptoms associated with higher odds for CVS included dyspnea and anosmia if tested at 3 and 4 weeks from symptom onset, respectively. Similar results were demonstrated when initial symptoms of fever, chills, and dizziness were tested at week 5 from symptom onset. There were no symptoms or comorbidities associated with CVS before 3 weeks of symptom onset, suggesting that testing for CVS before 3 weeks of symptom onset might not be warranted, regardless of symptoms or comorbidities.

Cough, sore throat, and myalgia were the most prevalent persistent symptoms at CVS, all of which are the most commonly reported symptoms associated with the post-infectious syndrome (PIS), [21, 22] a phenomenon that was first described by Bannister et.al. PIS is thought to be a clinical manifestation of persistent local and systemic immunologic derangements following the complex molecular interplay between a respiratory virus and the host immune system. [23] We speculate that the persistence of symptoms in our cohort at the time of CVS may be, at least in part, explained by the PIS. In a rapidly expanding epidemic, the approach to contact tracing and quarantine is challenging.

The majority of our patient population did not require hospitalization, and this significant difference may be due to the patients' age and absence of significant comorbidities as risk factors when compared to the hospitalized cases. The current data is derived from mostly young, healthy, and nonimmunocompromised subjects, which is consistent with the previous report from Chang D. et al. [28] J o u r n a l P r e -p r o o f With a substantial proportion of undefined pre-symptomatic transmission, measures such as enhanced personal hygiene and social distancing are likely to be key instruments for community disease control.

The primary limitation is the retrospective nature of this study and the symptom onset relying on patient recall upon confirmation of COVID-19, thus making it difficult to establish a clear timeline for CVS. All specimens were obtained from NP swabs; having a negative result does not rule out the presence of viral RNA. Finally, PCR tests can detect non-viable virus, and thus the prolonged RNA shedding may not correlate to persistence of infectious virus.

Patients with cough and/or fever at the time of laboratory-confirmed COVID-19 disease are more likely to have a persistent SARS-CoV-2 PCR test result if tested within 2 weeks of symptom onset than those without cough and/or fever. Those with asthma or receiving immunosuppression are less likely to achieve CVS within 3 weeks of symptom onset than those without these conditions. Patients with fever, chills and cough are more likely to achieve CVS at week 5 of symptom onset than those without the aforementioned symptoms. The findings of our study highlight the low yield of repeating a SARS-CoV-2 PCR test on an NP swab within 21 days of a laboratory-confirmed COVID-19 diagnosis to document CVS. 

Asymptomatic COVID-19 infection management: the key to stop COVID-19

Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis

Global Surveillance for human infection with coronavirus disease (COVID-19)

Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection

Temporal dynamics in viral shedding and transmissibility of COVID-19

Asymptomatic transmission, the Achilles' heel of current strategies to control COVID-19

Clinical progression of patients with COVID-19 in Shanghai

Risk factors for viral RNA shedding in COVID-19 patients

Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

The duration of viral shedding of discharged patients with severe COVID-19

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

SARS-CoV-2 viral load in clinical samples of critically ill patients

Early risk factors for the duration of SARS-CoV-2 viral positivity in COVID-19 patients

Factors associated with duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study

Analysis of factors affected the SARS-CoV-2 viral shedding time of COVID-19 patients in Anhui, China: a retrospective study

Factors associated with prolonged viral RNA shedding in patients with COVID-19

Prevention CfDCa. Symptoms of Coronavirus

Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)

Postinfectious cough: ACCP evidence-based clinical practice guidelines

Fatigue sensation following peripheral viral infection is triggered by neuroinflammation: who will answer these questions?

Post-infectious disease syndrome

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Viral infections in immunocompromised patients

Interpreting diagnostic tests for SARS-CoV-2

Persistent detection of SARS-CoV-2 RNA in patients and healthcare workers with COVID-19

Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan